VISEN Pharmaceuticals (02561) disclosed a next-day return reporting the on-market buyback of 8,600 ordinary shares on 1 June 2026 at prices ranging between HKD 21.54 and HKD 22.00, for a total consideration of HKD 0.19 million (volume-weighted average price: HKD 21.80).

Following the transaction, the company’s issued share capital (excluding treasury shares) fell from 113.88 million to 113.87 million shares, representing a marginal 0.008% reduction. Concurrently, VISEN’s treasury stock balance rose from 49,700 to 58,300 shares.

The repurchase formed part of a mandate granted on 27 June 2025 that authorises the company to buy back up to 11.39 million shares. Cumulatively, VISEN has now repurchased 58,300 shares under this authority, equivalent to 0.05% of the issued shares outstanding on the mandate date.

All 8,600 shares acquired on 1 June have been retained as treasury shares; no cancellations have been executed. In accordance with Hong Kong listing rules, VISEN is subject to a moratorium on issuing, selling or transferring treasury shares until 1 July 2026.